A5024892241- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- Autoimmune and Inflammatory Disorders Research
- Systemic Sclerosis and Related Diseases
- Biosimilars and Bioanalytical Methods
- Autoimmune Bullous Skin Diseases
- Lymphoma Diagnosis and Treatment
- Inflammatory Bowel Disease
- Toxin Mechanisms and Immunotoxins
- Chronic Lymphocytic Leukemia Research
- Orthopedic Infections and Treatments
- Spondyloarthritis Studies and Treatments
- HER2/EGFR in Cancer Research
- T-cell and B-cell Immunology
University of Leeds
2015-2024
Leeds Teaching Hospitals NHS Trust
2018-2024
NIHR Leeds Musculoskeletal Biomedical Research Unit
2015-2022
Chapel Allerton Hospital
2015-2021
Institute of Rheumatology
2017
Rawalpindi Medical University
2017
<ns4:p>The term spondyloarthritis refers to a group of immune-mediated diseases characterised by inflammation the axial skeleton, peripheral joints, and entheses. Ankylosing spondylitis (AS) is most common characteristic these entities even though it was first described over two centuries ago, understanding underlying disease mechanism remains incomplete. It known that around 40% patients with AS have subclinical bowel inflammation, suggesting origin could be in gut. Also, more genes new...
The tapering of biologic disease-modifying antirheumatic drug (b-DMARD) therapy for patients with rheumatoid arthritis (RA) in stable remission is frequently undertaken, but specific guidance on how to successfully taper lacking. objective this study identify predictors flare b-DMARD-induced clinical remission, who did or not follow structured b-DMARD tapering.
Abstract The presence of a disease continuum in inflammatory arthritis (IA) is recognised concept, with distinct stages from at-risk stage (presence anti citrullinated-peptide autoantibody) to diagnosis rheumatoid (RA), including therapy-induced remission. Despite T-cell dysregulation being key feature RA, there are few reports phenotyping along the IA-continuum. We investigated disturbances naïve, regulatory and inflammation related cell (IRC) CD4+ subsets 705 individuals across...
In a cross-sectional study, we evaluated the prevalence of 'multi-dimensional remission' (MDR) and its component parameters, assessed using objective measures in cohort RA patients treatment-induced DAS28-remission, their relationship with patient-reported outcome measures. We sought to confirm feasibility face validity MDR construct, providing platform for future longitudinal studies which clinical utility might be further established.605 were selected from an inflammatory arthritis...
<h3>Background:</h3> Tapering of disease-modifying therapy (DMARDs) is recommended by EULAR/ACR for rheumatoid arthritis (RA) patients who achieve sustained remission on stable therapy(1,2). However, there no guidance how to manage this in clinical practice. <h3>Objectives:</h3> We aimed assess flare over 12 months RA were offered structured tapering either conventional synthetic (cs) or biologic (b) DMARDs. <h3>Methods:</h3> (ACR/EULAR 2010) prospectively attending a clinic recruited when...
Background: Recommendations for the management of patients with RA who achieve stable clinical remission ≥6 months conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs) are to taper (with aim potentially stopping), although there currently no validated biomarkers permitting prediction sustained remission. Objectives: To assess rate over 12 In in remission, received either (i) structured tapering csDMARDs or (ii) continuation current therapy, focusing on value imaging...
<h3>Background</h3> Rheumatoid arthritis (RA) is an immune-mediated disease and primarily affects the synovium. The goal of treatment in RA remission (1), however we do not routinely assess immunological markers or perform ultrasound imaging to define this. <h3>Objectives</h3> We aimed explore clinical, characteristics patients clinical (DAS28<2.6). <h3>Methods</h3> A retrospective observational study was performed, using our inflammatory database. Patients were selected when fulfilling...
<h3>Background</h3> In the management of rheumatoid arthritis (RA), goal is remission. However it not easy to attain this in all patients. Its only high disease activity, but rather other factors like availability and cost biologics developing countries. Therefore various combination therapies conventional DMARDs are vogue such scenarios. Methotrexate (MTX) Leflunomide (LEF) an effective option which can be fairly utilized resource constraint settings induce <h3>Objectives</h3> To study...